Get started
10/7/24 - $elf - Too cheap to ignore ~$102. Buy.10/7/24 - vrockstar - NYSE:ELF Too cheap to ignore ~$102. Buy. - low 20s PE for mid 20s growth - AI will disrupt many categories, but makeup...? - cash generative. low (2% FCF) yield not "great" but growth is hard to ignore. also the price focused niche is great for the current environment. - solid brand - need to evaluate leadership (anyone have a view?) I'll revert here. - starting with a 1% position. think it could be a 2-3% position if/as we get into the 90s and even 80s (if/as) - mind the gaps in the chart from the 2023 period (flagged in grey) be safe out there. V
NYSE:ELFLong
by VROCKSTAR
3
Pepsico (PEP): Breakout or Rebound? Earnings Report IncomingThis week, Pepsico is set to announce its earnings, and we continue to monitor the same pattern that has persisted for a while now. PepsiCo's recent $1.2 billion acquisition of Siete Foods is a strategic move to expand Frito-Lay's "better-for-you" snack segment. Although the near-term impact on revenue is expected to be minimal, Citi predicts a modest contribution to overall growth. The deal is anticipated to close in 2025, broadening PepsiCo's multicultural portfolio. From a technical perspective, NASDAQ:PEP is still moving within the established range. We've added zones above and below the range and highlighted each instance when NASDAQ:PEP broke through the range. Except for one occurrence, all these breakouts provided good entry opportunities. The future direction remains uncertain, but the key is whether Pepsico can hold its level upon breaking through the range—it needs to hold to sustain momentum rather than falling back. For now, we continue to keep a close watch on NASDAQ:PEP and are waiting for this week's earnings report to provide further clarity. ✅
NASDAQ:PEP
by freeguy_by_wmc
SE fully valued, and at resistance. Not short, but getting readySea, Inc. ( NYSE:SE ) has been a nice turnaround story so far this year. The company operates in three segments, which I'd summarize as follows: Shopee (73% or revenue, 25%-30% annual revenue growth) is a fast-growing ecommerce platform in SE Asia. In Q2, its EBITDA margin was just below zero, which represents three consecutive quarters of improvement, but still worse than the year-ago margin of 7%. SeaMoney (14% or revenue, 20%+ annual revenue growth) is a digital payments and online lending platform, which obviously leverages the Shopee platform to expand its user base. This segment is highly profitable, with about a 32% EBITDA margin. Garena (13% or revenue, -17% annual revenue decline) is an online gaming platform and video game developer. This segment is also highly profitable with a most recent quarter EBITDA margin of almost 70%. The way I see it, there are three problems, two of which have gotten better, but one of which has gotten worse: The Shopee platform is the biggest and fastest growing segment, but it's also the least profitable. This has been the major millstone around the stock's neck for the last two years, The company believes that it is now on the cusp of turning a profit on the segment. But it seems uncertain, whether this business will ever really be able to earn its cost of capital. The Garena platform had lost its growth mojo. This seems to be turning a corner, now. Active users grew for the most recent 2 quarters, and bookings rose for four consecutive quarters. Revenue in Q2, however, was still down, both sequentially and over the past year. This stock has already more than doubled this year, and it's now quite expensive. SE trades at roughly 19-20x expected 2025 EV/EBITDA. For comparison: AMZN is at 13x, EBAY is at 10x, ETSY at 9x. Only its Asian competitor CPNG (23x) and South American MELI (24x) are more expensive. I believe that SE might be a compelling long-term opportunity, but for the next 2 to 4 weeks it looks like it's running on fumes. The stock has just broken through its 2023 high and is at a 2-year high. It's also just reached its VWAP since IPO for the first time since April 2022. I wouldn't be surprised if a lot of supply would come into play, right here at 90-91. If resistance doesn't materialize, I would contemplate a short position in the upper 90s.
NYSE:SEShort
by matthias
2
SasanSeifi|Can We Expect $80 or More?Hey there, ✌ NYSE:RDDT In the daily time frame, it can be observed that we have experienced an upward trend from the $50 mark, with the price currently moving within an ascending channel. At present, the price is situated at the midline of this channel. The outlook remains predominantly bullish, and it is expected that after a brief consolidation, the price could rise to the previous peak of $78. Furthermore, if the price breaks above the previous all-time high (ATH), we may witness further gains towards the targets of $80, $85, and even $90. To better understand the continuation of this upward trend, it will be crucial to observe how the price reacts to these anticipated levels. The potential trend is also illustrated in the accompanying chart. Key support levels for this bullish scenario are found between $65 and $60. If these supports are lost and the price stabilizes below them, the bullish analysis will lose its credibility. 💢 This is just my personal analysis, not financial advice. If you found this helpful, feel free to like and comment – I'd love to hear your thoughts! Happy trading! ✌😊
NYSE:RDDTLong
by SasanSeifi
Endava plc to begin new bull market?On the above 2-week chart price action has corrected 85%. Popular finance articles and now even legal action is proposed, everyone is a bear. “Investors who lost money on Endava plc(DAVA) should contact The Gross Law Firm about pending Class Action - DAVA” PR Newswire, Oct 7th Seriously? Price go down and your response is legal action?! That’s bitter. Should we be joining the bearish sentiment? Or cease an opportunity from angry sellers? ** The Technical analysis ** 1) Price action and RSI resistance breakouts. 2) Price action is on legacy support from January 2019! 3) No stock splits. 4) Regular bullish divergence, lots of it. Is it possible price action continues to correct? Sure. Is it probable? No Ww Type: Investment Risk: You decide Timeframe for long entry: Before the judge throws out the lawsuit and tells investors price action go down as well as up. Return: Will say so elsewhere
NYSE:DAVALong
by without_worries
7
BABA - Support and Resistance (Educational)Happy Day to all you traders out there! Alright, lets get down to business. Fact of the matter is, areas where price action previously found support likely will act as resistance in the future and vice versa. This is important for any trader out there that isn't interested in being an investor in a company and is only looking for short term upside. What we can see is that going back to BABA's early days listed on the NYSE in 2014/2015, we had significant resistance around the 120 level before BABA retreated to ~$59. It then overtook that level in 2017 and for a short period of time, tested that level and eventually blasted off to $320. Then, on the way down (eventually back to that $60 level - a huge loss for top buyers), it found resistance after it lost that $120 level. Well, here we are again. We're back near $120 now. If we can get through this level, we should see a move back to a level I've identified using the Trend-Based Fibonacci Extension tool (built into TradingView) which is around $140. You can see in late 2021 and early 2022, we found both support and resistance at that level. I'd expect we'll initially find resistance there and it matches with the 100% extension of the move I'm measuring (check out the video for a simpler explanation). Ultimately, short term, I'm looking for this $120 level to be reclaimed to get that move to $140, which I've been discussing here for a while. We'll see what happens in October which historically has been a bearish month, but so far it's not terrible. Safe trading out there, fellas!
NYSE:BABALong
by bitdoctor
NASDAQ: HTCR | Technical Review 07/10/2024​Supported by their strong profit forecast, we are starting to see investors building up position in Heartcore Enterprise Inc. (NASDAQ: HTCR) despite huge profit taking activity was seen in last Friday. Nevertheless, HTCR's share price was strongly supported around its current level, with the expectation to hold around $0.750 for the remaining of the week. We deem this as a Trading BUY opportunity for those who have not built any position on hand for HTCR.
NASDAQ:HTCRLong
by HASHInvests200
10/7/24 - $pep - Swing long into print10/7/24 :: VROCKSTAR :: NASDAQ:PEP Swing long into print - Keeping it small (tue AM EPS), just keeping the knife sharp - 20x NTM PE for a HSD EPS grower not "great" but this portfolio of brands and know Siete *tiny violin and salty tortilla-shaped tear* is a pretty good "LT" price www.fdiforum.net - the rub is stonk has been relatively flat for a while in an up market (red flag) - i think the analysis is as simple as this - 20x and have pricing power, 2.5% fcf yield +HSD fcf growth is better than cash, "consumer" on it's back but staples seem to do being well (look at grocery). if it's off on the day - i'd probably dip buy it for a more YE style swing. thoughts? V
NASDAQ:PEPLong
by VROCKSTAR
2
Pfizer Stock Rises on Report Starboard Takes $1Bln StakePfizer Inc. (NYSE: NYSE:PFE ), once a market darling during the COVID-19 pandemic thanks to its breakthrough vaccine, has seen its stock struggle over the past two years. The shares are trading roughly 30% lower than in 2019 and have faced immense pressure due to declining demand for its COVID-related products and a costly acquisition strategy. However, a new catalyst has emerged that may signal a turning point for the pharmaceutical giant—activist investor Starboard Value has reportedly taken a $1 billion stake in Pfizer (NYSE: NYSE:PFE ), setting the stage for a potential turnaround. Let's dive into the technical and fundamental aspects driving this story. A Billion-Dollar Vote of Confidence Starboard Value's stake in Pfizer (NYSE: NYSE:PFE ), valued at roughly $1 billion, is a clear signal that the activist hedge fund believes there is untapped value in the company. Starboard has a track record of targeting underperforming companies and pushing for strategic changes to unlock shareholder value. This time, Starboard appears to be focusing on Pfizer’s management, specifically CEO Albert Bourla, who has been criticized for his acquisition-heavy strategy since taking the helm in 2019. Under Bourla, Pfizer (NYSE: NYSE:PFE ) has spent close to $70 billion on acquisitions, including the $43 billion deal for Seagen in 2022, focused on cancer drugs. While Pfizer (NYSE: NYSE:PFE ) hoped these moves would diversify its revenue streams beyond COVID-19, many analysts and investors have questioned the returns on these investments, particularly after Pfizer (NYSE: NYSE:PFE ) recently had to recall a sickle cell drug it acquired in the $5 billion Global Blood Therapeutics acquisition. The drug Oxbryta, which brought in only $300 million last year, had to be pulled due to safety concerns, further denting investor confidence. Starboard’s approach reportedly includes reaching out to Ian Read, Pfizer’s former CEO, and Frank D’Amelio, its former CFO, both of whom had a more disciplined focus on cost management and investment in novel drugs during their tenure. Under Read, Pfizer shares more than doubled, while Bourla’s leadership has coincided with a significant erosion in shareholder value. To address these challenges, Pfizer (NYSE: NYSE:PFE ) has already initiated a $4 billion cost-cutting program and is planning further reductions. However, more than $100 billion in shareholder value has evaporated since the peak of the pandemic, putting immense pressure on management to act swiftly. Technical Outlook From a technical perspective, Pfizer’s stock has been in a downward trend since its pandemic highs in 2021. However, the recent news of Starboard’s involvement has injected new life into the stock, which is up around 3% in premarket trading. This spike is also above key moving averages, suggesting a potential shift in momentum. The (Relative Strength Index) RSI currently sits at 42.59, which is just below neutral territory. While not yet in the overbought range, this indicates the stock still has room to run, particularly as investor sentiment improves following the Starboard news. The RSI suggests that the stock may be exiting its oversold condition, aligning with a bullish outlook. Pfizer has been trading in a falling trend pattern, characterized by lower highs and lower lows. However, the recent surge in premarket trading suggests a potential break from this pattern. If the stock can maintain its momentum and break through key resistance levels, we could see a reversal in its overall trend. NYSE:PFE has moved above several key moving averages, which often serve as support and resistance levels. Breaking above these averages can be a bullish signal for traders, especially in combination with improving fundamentals driven by Starboard’s involvement. Market Performance vs. Peers Pfizer's shares have been relatively flat in 2024, underperforming the broader market, which has seen a 21% rise in the S&P 500. This poor performance is in part due to fading COVID-19-related revenues and costly acquisitions that have yet to yield significant returns. The company’s stock is currently about 50% below its pandemic peak. However, it’s worth noting that while Pfizer (NYSE: NYSE:PFE ) has underperformed, it still maintains a massive market capitalization, and its core pharmaceutical business remains strong. The company’s portfolio includes blockbuster drugs and a robust pipeline of potential therapies, particularly in oncology. Should Starboard’s involvement lead to a more disciplined approach to M&A and cost management, Pfizer could be well-positioned for a resurgence. Outlook: Can Starboard Revive Pfizer? While it’s too early to say definitively what Starboard's exact plans are for Pfizer, the involvement of an activist investor of this magnitude is often a positive signal for shareholders. Starboard has historically been successful in unlocking value in companies, and if Pfizer’s management is willing to make the necessary changes, we could see a significant turnaround in its stock price.
NYSE:PFELong
by DEXWireNews
JP Morgan Chase Exhibiting Signs of a Continuation to the UpsideUpcoming Earnings: JP Morgan Chase & Co. (ticker: JPM) is scheduled to report earnings before the market opens on 11 October. The consensus earnings per share (EPS) estimate for the fiscal quarter ending September 2024 is US$4.04. The reported EPS for the same quarter a year prior was US$4.33. Upside Strength; Price Rebounding from Ichimoku Cloud Basic chart analysis shows that the stock is in an uptrend, displayed through price trading above the 200-day simple moving average (white at US$194.91), structural higher highs and higher lows, and a rising Average Directional Index (ADX) indicator. Traders typically look for the ADX to climb above 25 to reflect strength in the trend. You will also see from the Ichimoku Indicator that the Ichimoku Cloud – formed by the Leading Span A at US$210.85 (green) and the Leading Span B (orange) at US$208.19 – has buyers and sellers battling for position within its limits. As of writing, the Leading Span A is above the Leading Span B, a bullish signal. However, Ichimoku traders will likely be cautious at current levels because the Ichimoku Conversion Line (blue at US$208.65) recently crossed below the Base Line (red at US$213.05), a bearish signal. Therefore, a crossover here back to the upside could trigger stronger commitment from bulls in this market (this is a confirmation signal that traders commonly employ for longs out of the Ichimoku Cloud). Another bullish confirmation signal often used is price crossing above the Base Line. Price Direction? As of current price levels, buyers are unlikely to commit. However, a price close above the Ichimoku Base line could attract bulls, with the Conversion Line crossing above the Base Line likely to fuel further buying and challenge all-time highs of US$225.48.
NYSE:JPMLong
by FPMarkets
AMAT - Applied Materials, Inc.Applied Materials, Inc. provides manufacturing equipment, services and software to the semiconductor, display and related industries. It operates through the following segments: Semiconductor Systems, Applied Global Services, and Display & Adjacent Markets. The Semiconductor Systems segment includes semiconductor capital equipment for etch, rapid thermal processing, deposition, chemical mechanical planarization, metrology and inspection, wafer packaging, and ion implantation. The Applied Global Services segment provides solutions to optimize equipment, performance, and productivity. The Display & Adjacent Markets segment offers products for manufacturing liquid crystal displays, organic light-emitting diodes, equipment upgrades, and other display technologies for TVs, monitors, laptops, personal computers, smart phones, and other consumer-oriented devices. The company was founded on November 10, 1967 and is headquartered in Santa Clara, CA.
NASDAQ:AMATLong
by Esmail_from_Kuwait